Cathepsin B abundance, activity and microglial localisation in Alzheimer's disease-Down syndrome and early onset Alzheimer's disease; the role of elevated cystatin B

被引:2
作者
Wu, Yixing [1 ]
Mumford, Paige [1 ]
Noy, Suzanna [2 ]
Cleverley, Karen [2 ]
Mrzyglod, Alicja [1 ]
Luo, Dinghao [1 ]
van Dalen, Floris [3 ,4 ]
Verdoes, Martijn [3 ,4 ]
Fisher, Elizabeth M. C. [2 ]
Wiseman, Frances K. [1 ]
机构
[1] UCL, UK Dementia Res Inst, Queen Sq, London WC1N 3BG, England
[2] UCL, Queen Sq Inst Neurol, Dept Neuromuscular Dis, Queen Sq, London WC1N 3BG, England
[3] Radboudumc, Dept Med Biosci, Geert Grooteplein Zuid 28, NL-6525 GA Nijmegen, Netherlands
[4] Inst Chem Immunol, Geert Grooteplein Zuid 28, NL-6525 GA Nijmegen, Netherlands
基金
英国医学研究理事会; 英国惠康基金;
关键词
Down syndrome; Alzheimer's disease; Cathepsin B; Cystatin B; MOUSE MODEL; UP-REGULATION; BRAIN; INDIVIDUALS; DYSFUNCTION; MEMORY;
D O I
10.1186/s40478-023-01632-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cathepsin B is a cysteine protease that is implicated in multiple aspects of Alzheimer's disease pathogenesis. The endogenous inhibitor of this enzyme, cystatin B (CSTB) is encoded on chromosome 21. Thus, individuals who have Down syndrome, a genetic condition caused by having an additional copy of chromosome 21, have an extra copy of an endogenous inhibitor of the enzyme. Individuals who have Down syndrome are also at significantly increased risk of developing early-onset Alzheimer's disease (EOAD). The impact of the additional copy of CSTB on Alzheimer's disease development in people who have Down syndrome is not well understood. Here we compared the biology of cathepsin B and CSTB in individuals who had Down syndrome and Alzheimer's disease, with disomic individuals who had Alzheimer's disease or were ageing healthily. We find that the activity of cathepsin B enzyme is decreased in the brain of people who had Down syndrome and Alzheimer's disease compared with disomic individuals who had Alzheimer's disease. This change occurs independently of an alteration in the abundance of the mature enzyme or the number of cathepsin B+ cells. We find that the abundance of CSTB is significantly increased in the brains of individuals who have Down syndrome and Alzheimer's disease compared to disomic individuals both with and without Alzheimer's disease. In mouse and human cellular preclinical models of Down syndrome, three-copies of CSTB increases CSTB protein abundance but this is not sufficient to modulate cathepsin B activity. EOAD and Alzheimer's disease-Down syndrome share many overlapping mechanisms but differences in disease occur in individuals who have trisomy 21. Understanding this biology will ensure that people who have Down syndrome access the most appropriate Alzheimer's disease therapeutics and moreover will provide unique insight into disease pathogenesis more broadly.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Further understanding the connection between Alzheimer's disease and Down syndrome
    Snyder, Heather M.
    Bain, Lisa J.
    Brickman, Adam M.
    Carrillo, Maria C.
    Esbensen, Anna J.
    Espinosa, Joaquin M.
    Fernandez, Fabian
    Fortea, Juan
    Hartley, Sigan L.
    Head, Elizabeth
    Hendrix, James
    Kishnani, Priya S.
    Lai, Florence
    Lao, Patrick
    Lemere, Cynthia
    Mobley, William
    Mufson, Elliott J.
    Potter, Huntington
    Zaman, Shahid H.
    Granholm, Ann-Charlotte
    Rosas, H. Diana
    Strydom, Andre
    Whitten, Michelle Sie
    Rafii, Michael S.
    ALZHEIMERS & DEMENTIA, 2020, 16 (07) : 1065 - 1077
  • [42] Down syndrome and Alzheimer's disease: Oxidative stress in the neurodegenerative process
    Cordeiro, Augusto Magno Tranquezi
    Singulani, Monique Patricio
    Talib, Leda Leme
    Forlenza, Orestes Vicente
    JOURNAL OF ALZHEIMERS DISEASE, 2025, 105 (01) : 258 - 267
  • [43] Assessing disease-modifying effects of norepinephrine in Down syndrome and Alzheimer's disease
    Ponnusamy, Ravikumar
    McNerney, M. Windy
    Moghadam, Shahrzad
    Salehi, Ahmad
    BRAIN RESEARCH, 2019, 1702 : 3 - 11
  • [44] Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome
    Startin, Carla M.
    Hamburg, Sarah
    Hithersay, Rosalyn
    Al-Janabi, Tamara
    Mok, Kin Y.
    Hardy, John
    Strydom, Andre
    Fisher, Elizabeth
    Nizetic, Dean
    Tybulewicz, Victor
    Karmiloff-Smith, Annette
    ALZHEIMERS & DEMENTIA, 2019, 15 (02) : 245 - 257
  • [45] Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome
    Cardenas, Ana M.
    Ardiles, Alvaro O.
    Barraza, Natalia
    Baez-Matus, Ximena
    Caviedes, Pablo
    ARCHIVES OF MEDICAL RESEARCH, 2012, 43 (08) : 645 - 654
  • [46] Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome
    Tramutola, Antonella
    Lanzillotta, Chiara
    Di Domenico, Fabio
    Head, Elizabeth
    Butterfield, D. Allan
    Perluigi, Marzia
    Barone, Eugenio
    NEUROBIOLOGY OF DISEASE, 2020, 137
  • [47] Alzheimer's disease and Down's syndrome: an in vivo MRI study
    Beacher, F.
    Daly, E.
    Simmons, A.
    Prasher, V.
    Morris, R.
    Robinson, C.
    Lovestone, S.
    Murphy, K.
    Murphy, D. G. M.
    PSYCHOLOGICAL MEDICINE, 2009, 39 (04) : 675 - 684
  • [48] Therapeutic potential of APP antisense oligonucleotides for Alzheimer's disease and down syndrome-related Alzheimer's disease
    Thirumalai, Srishruthi
    Patani, Rickie
    Hung, Christy
    MOLECULAR NEURODEGENERATION, 2024, 19 (01)
  • [49] Oxidation of aβ and plaque biogenesis in Alzheimer's disease and Down syndrome
    Head, E
    Garzon-Rodriguez, W
    Johnson, JK
    Lott, IT
    Cotman, CW
    Glabe, C
    NEUROBIOLOGY OF DISEASE, 2001, 8 (05) : 792 - 806
  • [50] Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome
    Zis, Panagiotis
    Strydom, Andre
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 114 : 3 - 9